醇通过激活BRCC3来缓解肺动脉高血压
Qing Yin1, Zhengqin Xiong1, Xinya Wang1
1Department of Cardiology, Affiliated Hospital of Yangzhou University, Yangzhou University, Institute of Cardiovascular Disease, Yangzhou Key Lab of Innovation Frontiers in Cardiovascular Disease, Yangzhou 225001, China.
概括
醇是一种天然化合物,通过重新平衡BMP/TGF-β通路,有效治疗肺高血压 (PH). 这项研究突出了醇作为PH和肺动脉高血压 (PAH) 的潜在治疗药物.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 肺动脉高血压 (PAH) 涉及血管重塑和右心室衰竭.
- 来自Paeonia suffruticosa的Paeonol具有抗炎和抗氧化特性.
- 目前尚不清楚Paeonol对PAH肺血管系统的影响.
研究的目的:
- 在肺高血压 (PH) 的小鼠模型中研究 paeonol 的保护作用.
- 阐明帕埃诺在PH中的作用背后的分子机制.
- 评估帕埃诺尔对肺动脉光滑肌细胞 (PASMC) 的影响.
主要方法:
- 利用小鼠PH模型来评估血液动力学,心声和病理学.
- 在PASMC增殖和亡方面进行了体外研究.
- 采用RNA测序,网络药理学,分子对接和表面等离子体共振 (SPR) 来识别目标和途径.
- 使用西式涂抹和免疫光学验证的结果.
主要成果:
- 在PH小鼠中,Paeonol显著降低了右心室缩压 (RVSP),高和肺血管重塑.
- 心声扫描证实了帕埃诺尔对右心室结构和功能的保护.
- 在体外,帕埃诺醇抑制了PASMC的扩散,并诱导了亡.
- 确定了骨形态遗传蛋白 (BMP) /转化生长因子-β (TGF-β) 途径作为一个关键的目标,醇直接与BRCC3结合以稳定BMP受体并恢复信号平衡.
结论:
- 醇通过BRCC3相互作用调节BMP/TGF-β信号通路来减弱PH,从而抑制血管重塑.
- 帕埃诺尔在治疗肺动脉高血压 (PAH) 中显示出显著的治疗潜力.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
613
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
613
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
471
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
471
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
509
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
509
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
625
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
625
01:30Pulmonary Hypertension: Classification and Pathogenesis
659
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
659
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
544
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
544